Cyclerion Therapeutics, Inc.

Historical 13F Holders

Symbol
CYCN
CUSIP
23255M204
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 23255M204 since 12/18/2024, newest first.

Filer % of Class Filed
Balyasny Asset Management L.P. 13G
7.3% 8/14/2026
Event 6/30/2026
ADAR1 Capital Management, LLC 13G
7.0% 8/14/2026
Event 6/30/2026
Peter M. Hecht 13D/A Amendment 8 19.4% 7/20/2026
Event 7/16/2026
FMR LLC 13G
15.0% 5/7/2026
Event 4/30/2026
J. Wood Capital Advisors LLC 13G
5.4% 10/17/2025
Event 3/25/2025
Tyndall Capital Partners, L.P. 13G/A Amendment 3 4.8% 8/14/2025
Event 6/30/2025
Tyndall Capital Partners, L.P. 13G/A Amendment 2 5.1% 5/15/2025
Event 3/31/2025
Peter M. Hecht 13D/A Amendment 7 27.9% 3/28/2025
Event 3/25/2025
American Endowment Foundation 13G/A Amendment 2 4.9% 2/12/2025
Event 12/31/2024
FMR LLC 13G/A Amendment 5
0.2% 2/12/2025
Event 12/31/2024
Slate Path Capital LP 13G/A Amendment 2
0% 12/6/2024
Event 11/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 22 4.95 M $16.8 M
2026 Q1 17 162 k $249 k
2025 Q4 19 296 k $376 k
2025 Q3 17 259 k $595 k
2025 Q2 18 363 k $1.06 M
2025 Q1 19 373 k $932 k
2024 Q4 20 382 k $1.23 M
2024 Q3 16 1.04 M $2.70 M
2024 Q2 19 1.05 M $2.41 M
2024 Q1 19 1.07 M $3.43 M
2023 Q4 18 1.07 M $3.59 M
2023 Q3 20 1.07 M $3.66 M
2023 Q2 21 995 k $4.10 M
2023 Q1 1 10.0 $4.00